Candido Riccardo, Wyne Kathleen, Romoli Ester
Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata di Trieste, Via Puccini 48/50, 34100, Trieste, Italy.
The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Diabetes Ther. 2018 Jun;9(3):927-949. doi: 10.1007/s13300-018-0422-4. Epub 2018 Apr 13.
Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.
Eli Lilly and Company.
基础-餐时胰岛素治疗（BBT）是指长效基础胰岛素与餐时速效胰岛素联合使用。甘精胰岛素100 U/mL和门冬胰岛素已上市多年，有大量证据支持这些药物在1型或2型糖尿病（T1DM、T2DM）患者的BBT或基础加餐时胰岛素治疗中的有效性和安全性。随着此类治疗方案中可使用的其他胰岛素越来越多，似乎有必要回顾一下关于甘精胰岛素100 U/mL和门冬胰岛素的BBT数据。在T1DM患者中，与使用人胰岛素作为基础和/或餐时成分的BBT相比，甘精胰岛素加门冬胰岛素的BBT能提供相似或更好的血糖控制，且夜间低血糖发生率更低，总体上与持续皮下胰岛素输注（CSII）给予门冬胰岛素所达到的血糖控制和严重低血糖发生率相似。评估甘精胰岛素加门冬胰岛素在T2DM患者中的BBT的研究也证实了这些胰岛素的有效性和安全性。现有数据表明，甘精胰岛素和门冬胰岛素的BBT在T1DM的儿童和成人人群以及T2DM的成人患者和65岁以上患者中提供相似水平的有效性和安全性。这些胰岛素制剂在不同种族人群以及患有T1DM或T2DM及合并症的患者中控制T2DM似乎也是安全有效的。
礼来公司。
